Abstract 2403P
Background
Deletion of CDKN2A, encoded for the tumor suppressor protein p16, represents a common cause for reduced or absent of p16 expression in tumor cells. In this study, we analyzed the impact of CDKN2A deletion on tumor aggressiveness, patient prognosis, and p16 expression in patients with urothelial bladder carcinomas.
Methods
CDKN2A copy number status was analyzed by fluorescence in-situ hybridization (FISH) on more than 2,500 urothelial bladder carcinomas in a tissue microarray format. Data of CDKN2A deletion were compared with p16 expression data measured by immunohistochemistry in a previous study. The results were compared with parameters of tumor phenotype and patient outcome.
Results
CDKN2A deletions occurred in 28% of 1,880 analyzable carcinomas, including 9% heterozygous and 19% homozygous CDKN2A deletions. The CDKN2A deletion rate, especially for homozygous deletions, increased from pTa G2 low (14%), to pTa G2 high (35%) but slightly decreased in pTa G3 (20%) carcinomas (p<0.0001). In muscle-invasive urothelial carcinomas, especially homozygous CDKN2A deletions were associated with advanced pT stage (p<0.0001), but unrelated to patient prognosis. However, in the subset of pT4 urothelial bladder carcinomas, a tendency for shorter overall survival for patients with CDKN2A deleted tumors was found (p=0.0828). CDKN2A deletions were significantly associated with p16 immunostaining (p<0.0001). Cancers without p16 immunostaining harbored in 62% of all cases a CDKN2A deletion and 97% of 343 homozygous CDKN2A deleted cancers were p16 negative. Cancers with CDKN2A deletion and negative p16 immunostaining were associated with advanced stage (p<0.0001) but unrelated to patient prognosis in muscle-invasive urothelial carcinomas.
Conclusions
CDKN2A deletions were most commonly seen in p16-negative carcinomas, supporting their role for p16 inactivation in urothelial bladder carcinomas. The association of CDKN2A deletion – especially homozygous deletion – with advanced stage may reflect increasing genomic instability going along with stage progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2380P - Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
Presenter: Nicolas Sayegh
Session: Poster session 24
2381P - Perceived unmet needs and challenges faced by patients with advanced bladder cancer (aBC) and their caregivers: Results of a social media listening (SML) study conducted in 5 European countries
Presenter: Stephane Schuck
Session: Poster session 24
2382P - EBANO study: Clinical characteristics, treatment patterns and survival results in patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in northern Spain
Presenter: Ricardo Fernandez-Rodriguez
Session: Poster session 24
2383P - Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Presenter: Faith Jawdat
Session: Poster session 24
2384P - Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study
Presenter: Eojin Kim
Session: Poster session 24
2385P - Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study
Presenter: Chantal Stockem
Session: Poster session 24
2386P - Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 24
2387P - Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Presenter: Kenneth Carson
Session: Poster session 24
2390P - Correlation between overall survival and bladder-intact event-free survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in Sweden
Presenter: Kelvin Kwok
Session: Poster session 24